Skip to main content

Articles

Perspectives
The Idealism of Youth
David B. Nash, MD, MBA
Read More
Original Research, Practice Management
Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports
Jean A. Gerlach; Brian Snow, PharmD; Katherine M. Prioli, MS; Ronald Vertsman, PharmD; Julie Patterson, PharmD, PhD; Laura T. Pizzi, PharmD, MPH
Read More
Foreword
Welcome to the Eleventh Annual Payers’ Guide to New FDA Approvals
Read More
FDA Approvals
Imbruvica (Ibrutinib) Receives Expanded Indication, in Combination with Rituximab, as First-Line Treatment for Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Mayzent (Siponimod) Approved for Relapsing Forms of Multiple Sclerosis, Including Active Secondary Progressive Disease
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Pemazyre (Pemigatinib) First Targeted Therapy FDA Approved for Cholangio­carcinoma with FGFR2 Biomarker
Loretta Fala
Read More
FDA Approvals
Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma
Loretta Fala
Read More
FDA Approvals
Trodelvy (Sacituzumab Govitecan-hziy) a New Targeted Therapy for Patients with Metastatic Triple-Negative Breast Cancer
Loretta Fala
Read More
FDA Approvals
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Loretta Fala
Read More
FDA Approvals
FDA Approvals of Brand-Name Prescription Drugs, January 1, 2019, Through June 15, 2020
Read More
Page 31 of 245
Results 301 - 310 of 2441